Immunome (NASDAQ:IMNM) Director Sells $543,090.40 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 20,840 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $26.06, for a total transaction of $543,090.40. Following the completion of the sale, the director directly owned 87,664 shares of the company’s stock, valued at $2,284,523.84. The trade was a 19.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The stock was sold at an average price of $27.25, for a total value of $301,058.00.
• On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The shares were sold at an average price of $26.23, for a total value of $1,633,892.93.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The shares were sold at an average price of $26.07, for a total value of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $397,362.88.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total value of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Stock Performance

IMNM stock opened at $27.99 on Thursday. Immunome, Inc. has a one year low of $8.66 and a one year high of $28.04. The stock has a market capitalization of $3.17 billion, a PE ratio of -11.06 and a beta of 2.08. The company has a fifty day moving average of $21.89 and a 200-day moving average of $22.20.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Equities analysts forecast that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunome

Several large investors have recently added to or reduced their stakes in IMNM. T. Rowe Price Investment Management Inc. grew its holdings in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares during the period. BlackRock Inc. purchased a new position in shares of Immunome during the 2nd quarter worth about $186,588,000. Vanguard Group Inc. boosted its position in shares of Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after acquiring an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA boosted its position in shares of Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after acquiring an additional 1,667,432 shares during the last quarter. Finally, State Street Corp grew its holdings in Immunome by 37.9% in the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after purchasing an additional 1,064,027 shares during the period. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on IMNM shares. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Leerink Partners dropped their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Citigroup reissued a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Finally, Wedbush boosted their price target on Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Immunome News Roundup

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
• Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
• Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.